[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-330465-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-330465-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-brd4-potential-therapeutic-strategy-for-head-and-neck-squamous-cell-carcinoma-review","Targeting BRD4 - Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)","","BRD4 is a chromatin-associated BET family protein that recognizes acetylated histones, recruits regulatory factors, and modulates gene expression through chromatin remodeling. Its cellular and epigenetic roles connect to normal development and to fibrosis and inflammation. Because BRD4 is frequently overexpressed and controls transcriptional programs driving proliferation, survival, migration, and drug resistance, BRD4 inhibition is explored as a cancer therapeutic strategy. For head and neck squamous cell carcinoma (HNSCC), BRD4 targeting may sensitize tumors to chemo- and radiotherapy, enabling de-intensification while reducing adverse effects, though mechanism-driven dosing requires further study.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-brd4-potential-therapeutic-strategy-for-head-and-neck-squamous-cell-carcinoma-review/330465/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-brd4-potential-therapeutic-strategy-for-head-and-neck-squamous-cell-carcinoma-review/330465.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is BRD4 and why is it relevant to cancer?","Question",{"text":63,"@type":64},"BRD4 is a BET family chromatin-associated protein that interacts with acetylated histones and recruits regulatory proteins to regulate gene expression and chromatin remodeling. Dysregulation of BRD4 can drive tumor cell proliferation, survival, migration, and drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How might BRD4 targeting improve treatment for head and neck squamous cell carcinoma (HNSCC)?",{"text":68,"@type":64},"Targeting BRD4 is proposed to sensitize HNSCC to chemo- and radiotherapy, supporting de-intensification of current treatment regimens and potentially reducing side effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges remain before BRD4-targeted drugs can be optimized for HNSCC patients?",{"text":72,"@type":64},"Further studies are required to clarify BRD4’s underlying mechanisms in HNSCC so that optimal dosing and administration of BRD4-targeted therapies can be determined.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},330465,1790380430,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","ONCOLOGY REPORTS 51: 74, 2024  \nTargeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)  \nVORAPORN YONGPRAYOON 1 , NAPASPORN WATTANAKUL 1 , WINNADA KHOMATE 1 , NATHAKRITAPITHANANGSIRI 1 , TARATHIPKASITIPRADIT 1 , DANUPON NANTAJIT 1 and MAHVASH TAVASSOLI2  \n1Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, Thailand; 2Centre for Host Microbiome Interactions, King's College London, London SE1 1UL, UK  \nReceived February 8, 2024; Accepted April 1, 2024  \nDOI: 10. 3892/or.2024.8733  \nAbstract. As a member of BET (bromodomain and extraterminal) protein family, BRD4 (bromodomain-containing protein 4) is a chromatin-associated protein that interacts with acetylated histones and actively recruits regulatory proteins, leading to the modulation of gene expression and chromatin remodeling. The cellular and epigenetic functions of BRD4 implicate normal development, fibrosis and inflammation . BRD4 has been suggested as a potential therapeutic target as it is often overexpressed and plays a critical role in regulating gene expression programs that drive tumor cell proliferation, survival, migration and drug resistance. To address the roles of BRD4 in cancer, several drugs that specifically target BRD4 have been developed. Inhibition of BRD4 has shown promising results in preclinical models, with several BRD4 inhibitors undergoing clinical trials for the treatment of various cancers. Head and neck squamous cell carcinoma (HNSCC), a heterogeneous group of cancers, remains a health challenge with a high incidence rate and poor prognosis . Conventional therapies for HNSCC often cause adverse effects to the patients. Targeting BRD4, therefore, represents a promising strategy to sensitize HNSCC to chemo-and radiotherapy allowing de‑intensification of the current therapeutic regime and subsequent reduced side effects. However, further studies are required to fully understand the underlying mechanisms of action of BRD4 in HNSCC in order to determine the optimal dosing and administration of BRD4-targeted drugs for the treatment of patients with HNSCC.  \nCorrespondence to: Dr Danupon Nantajit, Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Kamphaeng Phet 6 Road, Lak Si, Bangkok 10210, Thailand  \nE-mail: [danupon.nan@cra.ac.th](danupon.nan@cra.ac.th)  \nKey words: bromodomain-containing protein 4, head and necksquamous cell carcinoma, sensitization, de-escalation, targeted therapy  \nContents  \n1. Introduction  \n2. The normal functions of bromodomain-containing protein 4 (BRD4)  \n3. Roles of BRD4 in tumor development  \n4. DNA damage repair and therapy resistance  \n5. Epithelial mesenchymal transition (EMT) and cancer progression/aggressiveness  \n6. BRD4 in inflammation  \n7. The relationship between BRD4 and HPV  \n8. BRD4 roles and therapeutic approaches for head and necksquamous cell carcinoma  \n9. BRD4 and immune response  \n10. Resistance to bromodomain and extra-terminal (BET) inhibition  \n11. Clinical response to BRD4 targeting and adverse events  \n12. Toxicity of BET inhibition  \n13. Future perspective  \n1. Introduction  \nHead and neck squamous cell carcinoma (HNSCC) is oneof the most prevalent cancer globally, which arises from stratified mucosa of the mouth, trachea and larynx. Despite improved treatments, overall survival remains low, with more than 450,000 deaths in 2018 (1) . There is a rise in annual incidence of oropharynx squamous cell carcinoma, a subtype of HNSCC, over the past decade, within the non-smokers, non-alcoholics and aged \u003C50 years white male demographic group. This occurrence is associated with the human papillomavirus (HPV) infection, particularly HPV16, with the risk factor being an increase in sexual partners for oral or vaginal sex at a younger age (2) .  \nBromodomain protein 4 (BRD4) is one of the members of the bromodomain and extra-terminal (BET) family and a dual bromodomain protein consisting of two N-terminal b","cbCaitWwxjpSO4vj","https://ap.wps.com/l/cbCaitWwxjpSO4vj","pdf",608140,15,"English","# Introduction\n## The normal functions of BRD4\n## Roles of BRD4 in tumor development\n## DNA damage repair and therapy resistance\n## Epithelial mesenchymal transition (EMT) and cancer progression/aggressiveness\n## BRD4 in inflammation\n## The relationship between BRD4 and HPV\n## BRD4 roles and therapeutic approaches for head and neck squamous cell carcinoma\n## BRD4 and immune response\n## Resistance to BET inhibition\n## Clinical response to BRD4 targeting and adverse events\n## Toxicity of BET inhibition\n## Future perspective","[{\"question\":\"What is BRD4 and why is it relevant to cancer?\",\"answer\":\"BRD4 is a BET family chromatin-associated protein that interacts with acetylated histones and recruits regulatory proteins to regulate gene expression and chromatin remodeling. Dysregulation of BRD4 can drive tumor cell proliferation, survival, migration, and drug resistance.\"},{\"question\":\"How might BRD4 targeting improve treatment for head and neck squamous cell carcinoma (HNSCC)?\",\"answer\":\"Targeting BRD4 is proposed to sensitize HNSCC to chemo- and radiotherapy, supporting de-intensification of current treatment regimens and potentially reducing side effects.\"},{\"question\":\"What challenges remain before BRD4-targeted drugs can be optimized for HNSCC patients?\",\"answer\":\"Further studies are required to clarify BRD4’s underlying mechanisms in HNSCC so that optimal dosing and administration of BRD4-targeted therapies can be determined.\"}]","Targeting BRD4 - Potential therapeutic strategy for head and neck squamous cell carcinoma (Review) | PDF",1789989071,38]